Having trouble viewing this email? View in your browser.
ESCMID Logo

3 December 2019
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

 

ECCMID 2020 Abstract Submissions – A big thank you!

A big thanks to everyone who submitted an abstract for the
30th ECCMID in Paris 2020!
It was another record-breaking year, with submissions from
117 countries, yet again showing the growth and draw of ECCMID!
Abstract submitters will be notified of acceptance of their abstract(s) in mid-late January 2020, before the closure of the early-bird registration deadline. 

› Read more

ESCMID Postgraduate Technical Workshop:
Next-generation sequencing in routine clinical microbiology
and infectious diseases

Don’t miss out on the upcoming Workshop ‘Next-generation sequencing in routine clinical microbiology and infectious diseases’, coming up in LÝrenskog, Norway, from 13-16 May 2020.

Attendance grants are available for ESCMID members, apply online on the course website before 1 March 2020.

Find out about this and other upcoming ESCMID Postgraduate Courses and Workshops at the ESCMID 2020 Courses website.

› Read more

Join us at ECCMID 2020 to experience the Symposium “Tuberculosis: bringing new science to the clinic”
co-organized by ESGMYC (ESCMID Study Group for Mycobacterial Infections) and EPASG (ESCMID PK/PD of
Anti-Infectives Study Group)

Speakers: Ulrika Simonsson, Jan W. C. Alffenaar,
Stephen H. Gillespie, Delia Goletti

Tuberculosis (TB) continues to be a major killer amongst the infectious diseases and current treatment strategies have failed to prevent multi-drug resistance. Individualized therapies are required to maximize treatment efficacy and reduce the emergence of resistance. The first presentation will give an overview on preclinical data that informs on the PK/PD relationships of TB regimen of multi-drug combinations with a focus on pharmacodynamic interactions, which cannot be explored in the clinical setting, but need to be considered when developing a regimen for treatment of typical and atypical mycobacteria. The second and the third presentation of the symposium will elucidate new technologies to facilitate personalization of TB treatment. This will include minimally-invasive sampling of TB drugs to facilitate dose individualization in TB patients, and newly developed real-time biomarkers of mycobacterial burden and susceptibility testing. In the last presentation, cutting-edge research on host-related biomarkers will be presented including approaches to innovative host-directed therapies.

Visit ECCMID Live to discover more about our scientific programme and register now to take advantage of early registration discounts!

› Read more
 

Management of HCV infection in patients with haematological malignancies – an ESGVH survey

The ESGVH Executive Committee has endorsed a survey on the management of HCV infection in patients with haematological malignancies. Aims of the survey are to evaluate the willingness of DAAs prescribers to treat HCV infection during chemotherapy in patients with aggressive lymphoma, and report attitude of DAAs prescribers towards anticipating or delaying HCV treatment according to the presence of active haematological malignancies and towards transplant-related procedures. This survey might provide interesting data on the crucial issue of management of chronic HCV infection in this subset of immunocompromised patients.

To fill in the survey, please copy and paste the following link into your browser. Entries will be accepted until 19 January 2020. Feel free to share the link with your colleagues.

surveymonkey.com/r/ESGVH

› Read more
 

CMI Highlight: Bloodstream infections – Standard and progress in pathogen diagnostics

B. Lamy et al, on behalf of the ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), reviewed the literature for standard procedures and the progress in bloodstream infection (BSI) pathogen diagnostic in order to propose a new mindset to reach an improved diagnostic flow.

Blood culture performance relies largely on the quality of its pre-analytical phase that is improved with educational actions monitored by using key performance indicators, and external quality assessment. Advanced blood culture systems now provide tools for process automation, which proved efficient to facilitate effective training for improving blood collection. On analytic aspects, rapid methods for pathogen identification, and rapid antimicrobial susceptibility testing are reviewed. These technical developments call for improvements in all other steps, especially in logistics to give the full reciprocation of these techniques on patient management.

The authors conclude that progress in BSI pathogen diagnostics is based on a bundle approach that includes optimization of the pre-analytical parameters, rapid start of incubation, the use of rapid methods, re-organisation and a close involvement of antimicrobial stewardship teams. These developments lead to defining a new standard for bloodstream infection diagnostics.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.